Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol.
Die VA-HIT-Studie wurde von Rubins H.B., Robins S.J., Collins D. et al. veröffentlicht (Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.